Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin.

Antimicrobial Agents and Chemotherapy
S J CzinnS C Aronoff

Abstract

The presence of Campylobacter pyloridis in the gastric mucosa was recently linked to peptic ulcer disease. This study compared the inhibitory activity of three macrolide compounds (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin against 10 clinical isolates of C. pyloridis. The macrolides were equally effective against the test strains, with MICs ranging from 0.06 to 0.5 microgram/ml; rifampin was less active, with MICs ranging from 0.25 to greater than 1 microgram/ml. Erythromycin and the two new macrolide derivatives are potentially useful agents in the treatment of infections caused by C. pyloridis.

References

Feb 16, 1985·Lancet·C R Fricker, R W Park
Dec 1, 1985·Antimicrobial Agents and Chemotherapy·C A McNultyR Wise
Aug 1, 1985·Antimicrobial Agents and Chemotherapy·B M FloresW E Stamm
Dec 1, 1985·Journal of Clinical Microbiology·F MegraudH Lamouliatte
May 12, 1984·Lancet·C A McNulty, D M Watson
Sep 29, 1984·The Medical Journal of Australia·J R Warren
Oct 1, 1984·European Journal of Clinical Microbiology·G Kasper, N Dickgiesser
Jan 1, 1984·Journal of Clinical Pathology·T P RollasonJ M Rhodes

❮ Previous
Next ❯

Citations

Aug 1, 1988·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C A McNulty, J C Dent
Feb 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G J MalanoskiR C Moellering
Jan 1, 1990·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C S Goodwin, J A Armstrong
Sep 1, 1989·Antimicrobial Agents and Chemotherapy·H A Kirst, G D Sides
Sep 1, 1989·Antimicrobial Agents and Chemotherapy·J A García-RodríguezJ L Muñoz Bellido
Jan 1, 1988·Scandinavian Journal of Gastroenterology. Supplement·E Bayerdörffer, R Ottenjann
Apr 1, 1989·The Journal of Pediatrics·S J Czinn, W T Speck
Dec 1, 1991·FEMS Microbiology Letters·L CelliniB Dainelli
Jun 1, 1987·Pathologie-biologie·C FrelandH B Drugeon
Oct 12, 2001·Current Problems in Pediatric and Adolescent Health Care·B D Gold
Jan 1, 1990·Clinical Microbiology Reviews·G E Buck

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.